AstraZeneca PLC said Tuesday that initial results from a trial of datopotamab deruxtecan-based combinations show promising clinical activity in patients with advanced non-small-cell lung cancer.
The pharmaceutical giant said that the trial showed encouraging efficacy and safety results that justify further studies.
Datopotamab deruxtecan is being jointly developed by AstraZeneca and Daiichi Sankyo.
"We look forward to continuing this important research with the goal of providing a new, effective treatment option for patients with advanced non-small-cell lung cancer," Astra's Chief Medical Officer and Oncology Chief Development Officer Cristian Massacesi said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.